Aflibercept versus ranibizumab for cystoid macular oedema secondary to central retinal vein occlusion

被引：0
|
作者：
Karampelas, Michael [1 ]
Waxman, Jacob [1 ]
Barampouti, Foteini Faye [1 ]
机构：
[1] West Herts NHS Trust, Ophthalmol, London, England
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2018年 / 59卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
4286
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Spontaneous resolution of bilateral central retinal vein occlusion with cystoid macular oedema during pregnancy
    Li, Wenbo
    Ma, Minwang
    Hu, Bojie
    Dong, Lijie
    Li, Xiaorong
    ACTA OPHTHALMOLOGICA, 2019, 97 (03) : E482 - E483
  • [42] Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT
    Hykin, Philip
    Prevost, A. Toby
    Sivaprasad, Sobha
    Vasconcelos, Joana C.
    Murphy, Caroline
    Kelly, Joanna
    Ramu, Jayashree
    Alshreef, Abualbishr
    Flight, Laura
    Pennington, Rebekah
    Hounsome, Barry
    Lever, Ellen
    Metry, Andrew
    Poku, Edith
    Yang, Yit
    Harding, Simon P.
    Lotery, Andrew
    Chakravarthy, Usha
    Brazier, John
    HEALTH TECHNOLOGY ASSESSMENT, 2021, 25 (38) : 1 - +
  • [43] EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION
    Lotfy, Ayman
    Solaiman, Kamal A. M.
    Abdelrahman, Ayman
    Samir, Ahmed
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (09): : 1795 - 1800
  • [44] Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naive and refractory macular oedema in branch retinal vein occlusion
    Elkazza, Sumeia A.
    Hogg, H. D. Jeffry
    Di Simplicio, Sandro
    Dlay, Satnam S.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2022, 32 (01) : NP303 - NP304
  • [45] Aflibercept/bevacizumab/triamcinoloneLack of efficacy during treatment of macular oedema secondary to central retinal vein occlusion: case report
    Reactions Weekly, 2022, 1896 (1) : 26 - 26
  • [46] Intravitreal aflibercept for macular oedema due to branch retinal vein occlusion
    Clark, W. L.
    Brown, D.
    Stemper, B.
    ACTA OPHTHALMOLOGICA, 2014, 92
  • [47] Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
    Becky Pennington
    Abualbishr Alshreef
    Laura Flight
    Andrew Metry
    Edith Poku
    Philip Hykin
    Sobha Sivaprasad
    A. Toby Prevost
    Joana C. Vasconcelos
    Caroline Murphy
    Joanna Kelly
    Yit Yang
    Andrew Lotery
    Michael Williams
    John Brazier
    PharmacoEconomics, 2021, 39 : 913 - 927
  • [48] Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes
    Puche, Nathalie
    Glacet, Agnes
    Mimoun, Gerard
    Zourdani, Alain
    Coscas, Gabriel
    Soubrane, Gisele
    ACTA OPHTHALMOLOGICA, 2012, 90 (04) : 357 - 361
  • [49] Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
    Pennington, Becky
    Alshreef, Abualbishr
    Flight, Laura
    Metry, Andrew
    Poku, Edith
    Hykin, Philip
    Sivaprasad, Sobha
    Prevost, A. Toby
    Vasconcelos, Joana C.
    Murphy, Caroline
    Kelly, Joanna
    Yang, Yit
    Lotery, Andrew
    Williams, Michael
    Brazier, John
    PHARMACOECONOMICS, 2021, 39 (08) : 913 - 927
  • [50] Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry
    Hunt, Adrian R.
    Vuong Nguyen
    Creuzot-Garcher, Catherine P.
    Alforja, Socorro
    Gabrielle, Pierre-Henry
    Zarranz-Ventura, Javier
    Guillemin, Martin
    Fraser-Bell, Samantha
    Casaroli Marano, Ricardo P.
    Arnold, Jennifer
    McAllister, Ian L.
    O'Toole, Louise
    Gillies, Mark C.
    Barthelmes, Daniel
    Mehta, Hemal
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2022, 106 (08) : 1178 - 1184
12345